Lineage Cell Therapeutics Inc. (AMEX:LCTX) went up by 3.05% during the previous trading session, and it is maintaining the win ahead of Tuesday’s trading session. The share price of the Biotechnology giant went up by $1.01 to trade ended Tuesday trading at $0.98. This is up from the $0.9801 price recorded on Monday’s trading session. Thanks to this latest performance, LCTX is closer to the higher price 52-week target of $7.00 and further from the lowest price target of $3.00. Its performance from the start of the year has also been positive, with LCTX up by 13.48% year-to-date.
Lineage Cell Therapeutics Inc. (LCTX) started the day trading at $1.04 and recorded an intraday high of $1.04. It also recorded an intraday low of $1 during Tuesday’s trading session. Lineage Cell Therapeutics Inc. is a very active stock that recorded a trading volume that is less than -60.27% of the average daily trading volume on Tuesday. The stock’s trading volume on Tuesday was 592932, which is less than -60.27 of the total average daily trading volume of 950.30K.
Lineage Cell Therapeutics Inc. (AMEX:LCTX) 2020 Performance Impressive
The increase in LCTX’s stock price on Tuesday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of LCTX currently stands at $1.67, which is higher than the current trading price of the stock by 39.52%. However, LCTX’s current trading price is -90.57% lower than the 52-week low price of $0.53. In terms of trading volume, Lineage Cell Therapeutics Inc. currently experienced healthy participation during the last trading session. 592932 shares of Lineage Cell Therapeutics Inc. were traded on the stock exchange on Tuesday, which is less than -60.27% of the 950.30K average trading volume of the stock.
The performance of the stock has been positive over the past year. LCTX’s performance over the past one year has seen it plunge by -1.94%, while the stock has gone up by 48.73% in the last six months. The quarterly performance of LCTX currently stands at 45.97%, and it is up by 11.11% in the last month. The only negative figure was from the weekly performance, which currently reads -14.41%. At the time of writing LCTX’s report, the company has a total market cap of $155.99M, making it one of the largest publicly-traded companies in the world.Lineage Cell Therapeutics Inc. also has over 55 employees all over the world.
LCTX Insider Activities
For Lineage Cell Therapeutics Inc., insiders hold 42.80% of all company shares. The insider transactions over the past six months are up by 0.70%. During that period, insiders bought 30,900 shares in 2 transactions. In that same period, insiders sold 10,686 of their shares in 2 transactions. After these transactions, insiders at Lineage Cell Therapeutics Inc. now hold 8.95M shares, which is over 42.33% of the total company stocks. Institutional investors currently hold a large chunk of the LCTX shares, as they control 5.97% of the company’s total stock.
LCTX Fundamental Analysis
For Lineage Cell Therapeutics Inc., the stock’s diluted earnings per share (EPS) stands at -0.40. In the coming year, analysts expect the EPS to be -0.16. The stock’s EPS growth this year is 77.80%, 31.90% in the previous five years. In terms of revenue, Lineage Cell Therapeutics Inc.’s quarterly sales (YOY) is shrinking at -0.04, which is lower than the average annual revenue of 31.90% over the past half a decade.
The Return on Investment (ROI) on Lineage Cell Therapeutics Inc.’s stock currently stands at -27.80%. The gross margin of the company is 85.90%.
At the moment, Lineage Cell Therapeutics Inc.’s Total Debt to Equity ratio stands at 0.00, and they have a long-term Debt to Equity ratio of 0.00.
LCTX Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of LCTX currently stands at 5.87%, while the SMA50 is 16.47%. The biggest one is the SMA200, which is currently reading 11.21% ahead of Tuesday’s trading session. The Relative Strength Index of this stock is 55.58.